Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lisata Therapeutics, Inc. - Common Stock (NQ:LSTA)

2.256 UNCHANGED
Streaming Delayed Price Updated: 3:56 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lisata Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Lisata Therapeutics Announces Research License with Catalent
Catalent to evaluate certepetide with its SMARTag® antibody-drug conjugate platform 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Present at the Investival Showcase USA
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Present at the 2025 Sequire Investor Summit
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon and appendiceal cancers 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging
License provides Lisata’s innovative certepetide targeting agent for use with Kuva’s NanoMark™ MR imaging platform to advance non-invasive, high-precision cancer diagnostics 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Dave Mazzo, CEO of Lisata Therapeutics Inc. (NASDAQ: LSTA), to Present at NobleCon20
Via Investor Brand Network
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
Study will investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's platform technology, PeptiCRAd, and a checkpoint inhibitor in preclinical tumor models 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
Strategic partnership explores therapeutic effect of Lisata’s novel cyclic peptide product candidate, certepetide, in combination with bevacizumab 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
Study arm initiated based upon enthusiasm and at the request of investigators who participated in first-line cholangiocarcinoma cohort 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
From Lisata Therapeutics, Inc.; Quest Diagnostics, Haystack Oncology
Via GlobeNewswire
Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
Certepetide shown to promote immune cell infiltration into tumors and inhibit metastasis 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
From Lisata Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.